✦ LIBER ✦

P.3.e.004 Encounters of the third kind in schizophrenia: clinical specificities and treatment issues

✍ Scribed by M. Marinescu; C. Delbancut; S. Voillet; A.C. Ramond; Y. Bescond

Book ID: 118599340
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 58 KB
Volume: 22
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(12)70544-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.3.e.022 Schizophrenia and pregnancy: l

P.3.e.022 Schizophrenia and pregnancy: long-term study of a women-on-treatment sample in the community

✍ M.L. Zamarro; D. Crespo; A. Cordero; R. Gutierrez; J. Ramos 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 182 KB

P.3.c.040 The comparison of efficacy bet

P.3.c.040 The comparison of efficacy between aripiprazole and haloperidol in treatment of chronic schizophrenia and schizoaffective disorder: results for 16-week clinical study

✍ J.G. Kim; D.H. Cho; S.J. Lee; J.K. Lee; K.S. Wang; Y.I. Seo; S.J. Choi; M.J. Joo 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 76 KB

P.3.c.046 Efficacy and safety of JNJ 378

P.3.c.046 Efficacy and safety of JNJ 37822681, a fast dissociating D2 receptor antagonist, in the treatment of schizophrenia

✍ M. Schmidt; L. Janssens; J. Kent; I. Anghelescu; G. Hüsken; V. Sinha; E. Mannaer 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 62 KB

The treatment of negative symptoms and d

The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial

✍ Y. Lecrubier; P. Quintin; M. Bouhassira; E. Perrin; S. Lancrenon 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

Definitions, methodological and statisti

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

✍ Guilhot, J.; Baccarani, M.; Clark, R. E.; Cervantes, F.; Guilhot, F.; Hochhaus, 📂 Article 📅 2012 🏛 American Society of Hematology 🌐 English ⚖ 575 KB

Discovery of N-[(3R)-1-Azabicyclo[2.2.2]

Discovery of N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure−Activity Relationship

✍ Wishka, Donn G.; Walker, Daniel P.; Yates, Karen M.; Reitz, Steven C.; Jia, Shao 📂 Article 📅 2006 🏛 American Chemical Society 🌐 English ⚖ 200 KB